New drug combo shows promise against aggressive breast cancer
Disease control
Not yet recruiting
This study tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, given before surgery to people with stage II or III triple-negative breast cancer (TNBC). The goal is to see if this treatment can eliminate all signs of cancer by the time of surgery. About 5…
Phase: PHASE2 • Sponsor: Yantai Yuhuangding Hospital • Aim: Disease control
Last updated May 15, 2026 11:54 UTC